Allarity Therapeutics (ALLR) Short-Term Debt issuances (2021 - 2026)
Allarity Therapeutics' (ALLR) quarterly Short-Term Debt issuances came in at $20.0 million in Q1 2026, up 32886.89% on a QoQ basis from -$61000.0 in Q3 2021.
Allarity Therapeutics (ALLR) Short-Term Debt issuances (2021 - 2026) Analysis & Trends
Allarity Therapeutics (ALLR) has 2 years of Short-Term Debt issuances data on file, last reported at $20.0 million in Q1 2026.
- Quarterly Short-Term Debt issuances changed N/A year-over-year to $20.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.9 million (up 16855.46% YoY) and the FY2021 annual result came in at -$84000.0, down 200.0% from the prior year.
- Short-Term Debt issuances improved to $20.0 million in Q1 2026, from -$61000.0 in the prior quarter.
- In the past five years, Short-Term Debt issuances ranged from a high of $20.0 million in Q1 2026 to a low of $20.0 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Short-Term Debt issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Allarity Therapeutics | 22.75 Mn | 22.75 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 20.00 Mn |
| Mar 31, 2026 | 20.00 Mn |
| Sep 30, 2021 | -61,000.00 |
| Sep 30, 2021 | -61,000.00 |
| Jun 30, 2021 | -58,000.00 |
| Jun 30, 2021 | -58,000.00 |
| Mar 31, 2021 | 35,000.00 |
| Mar 31, 2021 | 35,000.00 |